🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The Cystic Fibrosis Foundation is hosting BreatheCon this week, on 24-25 Sep. The virtual event will provide a platform for the #CysticFibrosis community to share, connect and learn - it is an opportunity to support and inspire one another. Register here: rb.gy/ifzj3s

Join today’s webinar on ‘Other channels that modify CFTR containing epithelia’ from European Cystic Fibrosis Society, 3-4PM. Our Head of Biology, Henry Danahay, will speak on the potential of ENaC as a #therapeutic target to hydrate mucus in the #CysticFibrosis airway. rb.gy/jxim3r

. Emily's Entourage is approaching the $10M fundraising mark in its mission to drive #research & #drugdevelopment for #nonsensemutations of #CysticFibrosis, & we are proud to be sponsoring their annual gala event again this year. rb.gy/c7k6e7 #respiratorydisease

November is #COPDMonth! #COPD is a progressive #lungdisease that affects millions, but with early #diagnosis and #treatment, people with COPD can improve their quality of life and #BreatheBetter. Learn more to help raise awareness, Breathe Better: rb.gy/r8z5mu

Congratulations Emily's Entourage for hitting the $10M fundraising mark since founding, raising over $918,000 at its 10th winter gala! This achievement will support the charity’s goal of finding a cure for #nonsensemutations of #CF: rb.gy/c7k6e7 #respiratorydisease

We are pleased to welcome Dr Niyati Prasad as our Chief Medical Officer. Her extensive experience in #drugdevelopment will support the continued advancement of our novel #respiratory programmes through the #clinic. Read here: rb.gy/fc107j #research #cysticfibrosis

May is #CFAwarenessMonth! Join Emily's Entourage in uniting the #CysticFibrosis community to #CrossOutCF, sharing inspiring stories to raise awareness and accelerate innovative #drugdevelopment for #CF. We are proud to be a sponsor. Get involved here: rb.gy/h7be7s

We are pleased to join Emily's Entourage in #CFAwarenessMonth to unite the strengths of the #CysticFibrosis community and #CrossOutCF. Our #scientists are committed to delivering therapies aimed at treating all people with #CF, regardless of #genotype: rb.gy/h7be7s

Our Head of Development, Paul Russell, is presenting 'ETD001: a long-acting inhaled ENaC blocker is well tolerated in humans’ at the European Cystic Fibrosis Society next week. Join to learn more about Enterprise Therapeutics's development of #muco-regulatory therapies for #CF: rb.gy/jemppi

Why have previous attempts to target ENaC in the lungs of #CysticFibrosis patients failed? Don't miss Enterprise Therapeutics's Henry Danahay describe ETD001, a long acting inhaled ENaC blocker with the opportunity to treat all #CF patients, at European Cystic Fibrosis Society: rb.gy/soo8mk

Interested in the initial #data behind the safety, tolerability, and pharmacokinetic profile of ETD001, our novel muco-regulatory #drug for #cysticfibrosis? Join our poster presentation at the ERS International Congress to learn more: rb.gy/ty63wd ERS

A huge congratulations to Emily's Entourage on raising $975,669 (and counting) at its annual gala this year! We are proud to have returned as sponsors, to support the charity in its mission to find a cure for all with #CysticFibrosis. Learn more: bit.ly/3eJdH6M

Our Chief #Medical Officer, Dr Niyati Prasad, is presenting at #Clinical #Outsourcing Group UK. Join Niyati to hear key insights on identifying accurate endpoints to improve clinical study design for #rarediseases. Learn more and register here: bit.ly/3X0Wh6P #COGUK

Every May, the #cysticfibrosis community comes together for #CFAwarenessMonth, with the aim to raise awareness and find a cure for all people with #CF. Joining this mission, we are dedicated to the delivery of novel muco-regulatory treatments for CF: bit.ly/3o6E2An

In conversation with ICT Magazine, our #CMO, Dr Niyati Prasad shares her insight on conducting #clinicaltrials for #rarediseases, from how #researchers can best select primary and secondary endpoints to the role of ePROs. Read here: bit.ly/3C6hZ0p

#CysticFibrosis affects over 10,800 people in the UK. Join us for #CFWeek to raise awareness and celebrate the innovative progress that has already been made in CF #research, and the exciting breakthroughs on the horizon. Get involved with Cystic Fibrosis Trust here: rb.gy/li8ux

💬 In an exclusive interview with Endpoints News, our CEO John Ford outlines our aim to achieve #clinical #proofofconcept for ETD001 in #cysticfibrosis by mid-2025, following the close of our £26m #SeriesB follow-on #investment. Read the interview here: rb.gy/lkd51n

We are taking a step back from X. Follow our LinkedIn page: rb.gy/pcic21 , and visit our website for the latest updates: rb.gy/g2wrk1